Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck

Oral Oncol. 2021 Jan:112:104984. doi: 10.1016/j.oraloncology.2020.104984. Epub 2020 Sep 1.

Authors

Ruth Gabriela Herrera Gómez¹, Khalil Saleh², Lamia Mayache², Mariana Iacob², Neus Baste², Caroline Even²

Affiliations

¹ Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: gabriela.herrera-gomez@chuv.ch.
² Department of Head and Neck Surgical & Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

PMID: 32888816
DOI: 10.1016/j.oraloncology.2020.104984

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anaphylaxis / etiology
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / immunology
Antineoplastic Agents, Immunological / therapeutic use*
Carboplatin / administration & dosage
Carboplatin / adverse effects
Cetuximab / adverse effects
Cetuximab / immunology
Cetuximab / therapeutic use*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Maintenance Chemotherapy / methods*
Male
Middle Aged
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / radiotherapy
Neoplasms, Second Primary / surgery
Paclitaxel / administration & dosage
Paclitaxel / adverse effects
Palliative Care
Panitumumab / therapeutic use*
Progression-Free Survival
Randomized Controlled Trials as Topic
Research Design
Squamous Cell Carcinoma of Head and Neck / drug therapy*
Squamous Cell Carcinoma of Head and Neck / ethnology
Tongue Neoplasms / drug therapy*
Tongue Neoplasms / radiotherapy
Tongue Neoplasms / surgery

Substances

Antineoplastic Agents
Antineoplastic Agents, Immunological
Panitumumab
Carboplatin
Paclitaxel
Cetuximab